In a Key Win for Parse, Patent Trial and Appeal Board Invalidates 10x Genomics Patent Claims
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
10x Genomics Announces Its Chromium Single Cell Gene Expression And Xenium In Situ Platforms Were Used In A Publication, Featured On The Cover Of Cancer Cell, Shedding Light On The Role Of Fibrotic Scars In Glioblastoma Treatment Recurrence
Shareholders in 10x Genomics (NASDAQ:TXG) Have Lost 87%, as Stock Drops 7.8% This Past Week
Torex Gold Resources Analyst Ratings
Stephens & Co. Reiterates Overweight on 10x Genomics, Maintains $30 Price Target